Taiwanese Journal of Obstetrics and Gynecology
Volume 46, Issue 1 , Pages 26-32, March 2007

Molecular Carcinogenesis of Endometrial Cancer

  • Fu-Shing Liu

      Affiliations

    • Corresponding Author InformationCorrespondence to: Dr Fu-Shing Liu, Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, 160, Taichung Kang Road, Section 3, Taichung, Taiwan

Department of Obstetrics and Gynecology, Taichung Veterans General Hospital, and Department of Obstetrics and Gynecology, Chung-Shan Medical University, Taichung, Taiwan

Accepted 16 August 2006.

Article Outline

Summary 

In 1983, Bokhman proposed a dualistic model of endometrial tumorigenesis based on the clinical observations and clinicopathologic correlations. The majority of endometrial cancers (approximately 70–80%), designated as type I carcinomas, follow the estrogen-related pathway. Histologically, most of the type I tumors seem to arise in the background of hyperplastic endometrium, show an endometrioid differentiation, and are of low grade. Clinically, they are overall characterized by a favorable behavior. Another 10–20% of endometrial cancers, designated as type II carcinomas, follow the estrogen-unrelated pathway and arise in the background of atrophic endometrium. Type II tumors usually occur at an older age, approximately 5–10 years later than type I tumors. They are typically high-grade carcinomas of nonendometrioid differentiation, most frequently serous, less frequently clear cell. Type II carcinomas behave as an aggressive clinical course and poor prognosis. This dualistic model was subsequently supported by the molecular studies, approximately a decade later. At present, endometrioid and serous carcinoma, which represent the major phenotypes of types I and II endometrial carcinomas, respectively, are characterized by distinctive types of genetic instability and molecular alterations. In endometrioid (type I) carcinoma, four major genetic changes are responsible for the tumorigenesis, i.e. silencing of PTEN tumor suppressor gene, presence of microsatellite instability due to alterations of the mismatch repair genes, mutation of K-ras protooncogene, and alteration of β-catenin gene. On the other hand, p53 mutation and overexpression of Her2/neu oncogene are two major genetic alterations in serous and clear cell (type II) carcinomas. However, like in any model, there is evidence for exceptions. Many endometrial carcinomas are in the gray zone with overlapping clinical, morphologic, immunohistochemical, and molecular features of types I and II endometrial cancers. Finally, a small group of endometrial carcinoma is noted to be hereditary. It is known as the most common extracolonic malignancy in hereditary nonpolyposis colorectal cancer (Lynch syndrome), an autosomal dominantly inherited disorder of cancer susceptibility. Inactivation of the mismatch repair genes MSH2 and MSH6 seems to play a central role in the tumorigenesis.

Key Words:  carcinogenesis , endometrial carcinoma , genetic alteration

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Gruber SB , Thompson WD . A population-based study of endometrial cancer and familial risk in younger women: Cancer and Steroid Hormone Study Group . Cancer Epidemiol Biomarkers Prev . 1996;5:411–417
  2. Bokhman JV . Two pathogenetic types of endometrial carcinoma . Gynecol Oncol . 1983;15:10–17
  3. Potischman N , Hoover RN , Brinton LA , et al.   Case-control study of endogenous steroid hormones and endometrial cancer . J Natl Cancer Inst . 1996;88:1127–1135
  4. Lax SF , Pizer ES , Ronnett BM , Kurman RJ . Comparison of estrogen and progesterone receptor, Ki67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation . Hum Pathol . 1998;29:924–931
  5. Sherman ME , Bur ME , Kurman RJ . p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorogenesis . Hum Pathol . 1995;26:1268–1274
  6. Ambros RA , Sherman ME , Zahn CM , Bitterman P , Kurman RJ . Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation . Hum Pathol . 1995;26:1260–1267
  7. Lax SF , Pizer ES , Ronnett BM , Kurman RJ . Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression . Hum Pathol . 1998;29:551–558
  8. Mutter GL . Pten, a protean tumor suppressor . Am J Pathol . 2001;158:1895–1898
  9. Wu H , Goel V , Haluska FG . PTEN signaling pathways in melanoma . Oncogene . 2003;22:3113–3122
  10. Mutter GL , Lin MC , Fitzgerald JT , et al.   Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers . J Natl Cancer Inst . 2000;92:924–930
  11. Salvesen HB , MacDonald N , Ryan A , et al.   PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma . Int J Cancer . 2001;91:22–26
  12. Risinger JI , Hayes K , Maxwell GL , Carney ME , Barrett JC , Berchuck A . PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics . Clin Cancer Res . 1998;4:3005–3010
  13. Burks RT , Kessis TD , Cho KR , Hedrick L . Microsatellite instability in endometrial carcinoma . Oncogene . 1994;9:1163–1166
  14. Caduff RF , Johnston CM , Svoboda Newman SM , Poy EL , Merajver SD , Frank TS . Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma . Am J Pathol . 1996;148:1671–1678
  15. MacDonald ND , Salvesen HB , Ryan A , Iversen OE , Akslen LA , Jacobs IJ . Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas . Cancer Res . 2000;60:1750–1752
  16. Esteller M , Levine R , Baylin SB , Ellenson LH , Herman JG . MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas . Oncogene . 1998;17:2413–2417
  17. Salvesen HB , MacDonald N , Ryan A , et al.   Methylation of hMLH1 in a population-based series of endometrial carcinomas . Clin Cancer Res . 2000;6:3607–3613
  18. Staebler A , Lax SF , Ellenson LH . Altered expression of hMLH1 and hMSH2 protein in endometrial carcinomas with microsatellite instability . Hum Pathol . 2000;31:354–358
  19. Stefansson I , Akslen LA , MacDonald N , et al.   Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study . Clin Cancer Res . 2002;8:138–143
  20. Katabuchi H , van Rees B , Lambers AR , et al.   Mutations in DNA mismatch repair genes are not responsible for microsatellite instability in most sporadic endometrial carcinomas . Cancer Res . 1995;55:5556–5560
  21. Goodfellow PJ , Buttin BM , Herzog TJ , et al.   Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers . Proc Natl Acad Sci USA . 2003;100:5908–5913
  22. Maxwell GL , Risinger JI , Alvarez AA , Barrett JC , Berchuck A . Favorable survival associated with microsatellite instability in endometrioid endometrial cancers . Obstet Gynecol . 2001;97:417–422
  23. Caduff RF , Johnston CM , Frank TS . Mutations of the Ki-ras oncogene in carcinoma of the endometrium . Am J Pathol . 1995;146:182–188
  24. Semczuk A , Schneider-Stock R , Berbec H , Marzec B , Jakowicki JA , Roessner A . K-ras exon 2 point mutations in human endometrial cancer . Cancer Lett . 2001;164:207–212
  25. Sasaki H , Nishii H , Takahashi H , et al.   Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma . Cancer Res . 1993;53:1906–1910
  26. Lagarda H , Catasus L , Arguelles R , Matias-Guiu X , Prat J . K-ras mutation in endometrial carcinoma with microsatellite instability . J Pathol . 2001;193:193–199
  27. Ikeda T , Yoshinaga K , Suzuki A , Sakurada A , Ohmori H , Horii A . Anticorresponding mutations of the KRAS and PTEN genes in human endometrial cancer . Oncol Res . 2000;7:567–570
  28. Saegusa M , Hashimura M , Yoshida T , Okayasu I . Betacatenin mutations and aberrant nuclear expression during endometrial tumorigenesis . Br J Cancer . 2001;84:209–217
  29. Logan CY , Nusse R . The Wnt signaling pathway in development and disease . Annu Rev Cell Dev Biol . 2004;20:781–810
  30. Palacios J , Catasus L , Moreno Bueno G , Matias Guiu X , Prat J , Gamallo C . Betaand gamma-catenin expression in endometrial carcinoma. Relationship with clinicopathological features and microsatellite instability . Virchows Arch . 2001;438:464–469
  31. Strauli P , Haemmerli G . The role of cancer cell motility in invasion . Cancer Metastasis Rev . 1984;3:127–141
  32. Volk T , Geiger B , Raz A . Motility and adhesive properties of high and low-metastatic murine neoplastic cells . Cancer Res . 1984;44:811–824
  33. Holcomb K , Delatorre R , Pedemonte B , McLeod C , Anderson L , Chambers J . E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium . Obstet Gynecol . 2002;100:1290–1295
  34. Mell LK , Meyer JJ , Tretiakova M , et al.   Prognostic significance of E-cadherin protein expression in pathological stage I–III endometrial cancer . Clin Cancer Res . 2004;10:5546–5553
  35. Scholten AN , Aliredjo R , Creutzberg CL , Smit VT . Combined E-cadherin, alpha-catenin, and beta-catenin expression is a favorable prognostic factor in endometrial carcinoma . Int J Gynecol Cancer . 2006;16:1379–1385
  36. Salvesen HB , Das S , Akslen LA . Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis . Clin Cancer Res . 2000;6:153–159
  37. Milde-Langosch K , Riethdorf L , Bamberger AM , Loning T . P16/MTS1 and pRB expression in endometrial carcinomas . Virchows Arch . 1999;434:23–28
  38. Tsuda H , Yamamoto K , Inoue T , Uchiyama I , Umesaki N . The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma . Br J Cancer . 2000;82:675–682
  39. Yanokura M , Banno K , Susumu N , et al.   Hypermethyltion in the p16 promoter region in the carcinogenesis of endometrial cancer in Japanese patients . Anticancer Res . 2006;26:851–856
  40. Salvesen HB , Kumar R , Stefansson I , et al.   Low frequency of BRAF and CDKN2A mutations in endometrial cancer . Int J Cancer . 2005;115:930–934
  41. Lax SF , Kendall B , Tashiro H , Slebos RJ , Hedrick L . The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways . Cancer . 2000;88:814–824
  42. Koul A , Willen R , Bendahl PO , Nilbert M , Borg A . Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis . Cancer . 2002;94:2369–2379
  43. Ioffe OB , Papadimitriou JC , Drachenberg CB . Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium . Hum Pathol . 1998;29:1150–1159
  44. Williams JA , Wang ZR , Parrish RS , Hazlett LJ , Smith ST , Young SR . Fluorescence in situ hybridization analysis of FER2/neu, c-myc, and p53 in endometrial cancer . Exp Mol Pathol . 1999;67:135–143
  45. Matias-Guiu X , Catasus L , Bussaglia E , et al.   Molecular pathology of endometrial hyperplasia and carcinoma . Hum Pathol . 2001;32:569–577
  46. Lax SF . Molecular genetic pathways in various types of endometrioid carcinoma: from a phenotypical to a molecularbased classification . Virchows Arch . 2004;444:213–223
  47. Dong JT , Lamb PW , Rinker-Schaeffer CW , et al.   KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2 . Science (Washington DC) . 1995;268:884–886
  48. Liu FS , Dong JT , Chen JT , et al.   KAI1 metastasis suppressor protein is down-regulated during the progression of human endometrial cancer . Clin Cancer Res . 2003;9:1393–1398
  49. Liu FS , Chen JT , Hsieh YT , et al.   Loss of Smad4 protein expression occurs infrequently in endometrial carcinomas . Int J Gynecol Pathol . 2003;22:347–352
  50. Piestrzeniewicz-Ulanska D , Brys M , Semczuk A , Rechberger T , Jakowicki JA , Krajewska WM . TGF-beta signaling is disrupted in endometrioid-type endometrial carcinomas . Gynecol Oncol . 2004;95:173–180
  51. Tashiro H , Isacson C , Levine R , Kurman RJ , Cho KR , Hedrick L . p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis . Am J Pathol . 1997;150:177–185
  52. Tashiro H , Blazes MS , Wu R , et al.   Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies . Cancer Res . 1997;57:3935–3940
  53. Tashiro H , Lax SF , Gaudin pb , Isacson C , Cho KR , Hedrick L . Microsatellite instability is uncommon in uterine serous carcinoma . Am J Pathol . 1997;150:75–79
  54. Catasus L , Machin P , Matias Guiu X , Prat J . Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases . Hum Pathol . 1998;29:1160–1164
  55. Halperin R , Zehavi S , Habler L , Hadas E , Bukovsky I , Schneider D . Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium . Eur J Gynaecol Oncol . 2001;22:122–126
  56. Rolitsky CD , Theil KS , McGaughy VR , Copeland LJ , Niemann TH . HER-2/neu amplification and overexpression in endometrial carcinoma . Int J Gynecol Pathol . 1999;18:138–143
  57. Moreno-Bueno G , Hardisson D , Sarrio D , et al.   Abnormalities of Eand P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia . J Pathol . 2003;199:471–478
  58. Schlosshauer PW , Ellenson LH , Soslow RA . Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype . Mod Pathol . 2002;15:1032–1037
  59. Lax SF , Abeler VM , Regitnig P . Molecular genetic analysis of endometrial carcinoma: evidence for 2 genetically distinctive entities . Virchows Arch . 2001;439:247–252
  60. Ho ESC , Lai CR , Hsieh YT , Chen JT , Hung MJ , Liu FS . p53 mutation is infrequent in clear cell carcinoma of the ovary . Gynecol Oncol . 2001;80:189–193
  61. Zorn KK , Bonome T , Gangi L , et al.   Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer . Clin Cancer Res . 2005;11:6422–6430
  62. Kanaya T , Kyo S , Maida Y , et al.   Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers . Oncogene . 2003;22:2352–2360
  63. Lynch HT , Smyrk TC , Watson P , et al.   Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review . Gastroenterology . 1993;104:1535–1549
  64. Watson P , Vasen HF , Mecklin JP , Jarvinen H , Lynch HT . The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer . Am J Med . 1994;96:516–520
  65. Vasen HF , Watson P , Mecklin JP , et al.   The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer . Anticancer Res . 1994;14:1675–1678
  66. Peltomaki P , Vasen HF . The International Collaborative Group on HNPCC. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study . Gastroenterology . 1997;113:1146–1158
  67. Miyaki M , Konishi M , Tanaka K , et al.   Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer . Nat Genet . 1997;17:271–272
  68. Schweizer P , Moisio AL , Kuismanen SA , et al.   Lack of MSH2 and MSH6 characterizes endometrial but not colon carcinomas in hereditary nonpolyposis colorectal cancer . Cancer Res . 2001;61:2813–2815
  69. Parc YR , Halling KC , Burgart LJ , et al.   Microsatellite instability and hMLH1/hMSH2 expression in young endometrial carcinoma patients: association with family history and histopathology . Int J Cancer . 2000;86:60–66
  70. de Leeuw WJ , Dierssen J , Vasen HF , et al.   Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumors from HNPCC patients . J Pathol . 2000;192:328–335
  71. Sandles LG . Familial endometrial adenocarcinoma . Clin Obstet Gynecol . 1998;41:167–171
  72. Ollikainen M , Abdel-Rahman WM , Moisio AL , et al.   Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? . J Clin Oncol . 2005;23:4609–4616
  73. Risinger JI , Maxwell GL , Chandramouli GV , et al.   Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer . Cancer Res . 2003;63:6–11

PII: S1028-4559(08)60102-3

doi:10.1016/S1028-4559(08)60102-3

Taiwanese Journal of Obstetrics and Gynecology
Volume 46, Issue 1 , Pages 26-32, March 2007

Article Tools